Treatment for polycystic ovaries

Reading File
Finding Sources
Searching PubMed

"polycystic ovary syndrome" AND treatment

Searching Images

polycystic ovary syndrome PCOS ultrasound diagram

This composite educational graphic illustrates the relationship between BOP1 expression and polycystic ovary syndrome (PCOS). Panel A presents an anatomical diagram of a transvaginal ultrasound procedure alongside two actual ultrasound images comparing a 'Normal' ovary to a 'PCOS' ovary. The PCOS ovary demonstrates classic diagnostic features including enlargement and a 'string of pearls' appearance with multiple peripherally located, small, hypoechoic antral follicles. Panels B through E are scatter plots with linear regression lines showing clinical correlations in PCOS patients. These graphs demonstrate that relative BOP1 mRNA expression in granulosa cells is negatively correlated with four key clinical indicators: Antral Follicle Count (AFC) (r = -0.6082), Body Mass Index (BMI) (r = -0.4798), Serum Testosterone levels (r = -0.4262), and Anti-Müllerian Hormone (AMH) levels (r = -0.4674). All correlations are statistically significant (p < 0.05). This visual data suggests that downregulation of the BOP1 gene is associated with increased severity of PCOS phenotypic markers and hormonal imbalances.

This composite educational graphic illustrates the relationship between BOP1 expression and polycystic ovary syndrome (PCOS). Panel A presents an anatomical diagram of a transvaginal ultrasound procedure alongside two actual ultrasound images comparing a 'Normal' ovary to a 'PCOS' ovary. The PCOS ovary demonstrates classic diagnostic features including enlargement and a 'string of pearls' appearance with multiple peripherally located, small, hypoechoic antral follicles. Panels B through E are scatter plots with linear regression lines showing clinical correlations in PCOS patients. These graphs demonstrate that relative BOP1 mRNA expression in granulosa cells is negatively correlated with four key clinical indicators: Antral Follicle Count (AFC) (r = -0.6082), Body Mass Index (BMI) (r = -0.4798), Serum Testosterone levels (r = -0.4262), and Anti-Müllerian Hormone (AMH) levels (r = -0.4674). All correlations are statistically significant (p < 0.05). This visual data suggests that downregulation of the BOP1 gene is associated with increased severity of PCOS phenotypic markers and hormonal imbalances.

This diagnostic image is a transvaginal ultrasound (sonogram) of a human ovary, illustrating the classic morphological features of polycystic ovary syndrome (PCOS). The image shows an enlarged ovary containing numerous small, well-defined, hypoechoic (fluid-filled) cystic structures distributed primarily in the peripheral stroma, often referred to as the 'string of pearls' sign. There are at least eight visible follicles of varying diameters. Two linear calipers mark the dimensions of the ovary, with measurements recorded at 2.54 cm and 1.74 cm. The ovarian stroma appears relatively hyperechoic and prominent. The image also exhibits characteristic ultrasound speckle artifact throughout the tissue. This visual is used in medical education to demonstrate the 'polycystic' component of the Rotterdam criteria for diagnosing PCOS, emphasizing the specific distribution and quantity of follicles and the increase in overall ovarian volume.

This diagnostic image is a transvaginal ultrasound (sonogram) of a human ovary, illustrating the classic morphological features of polycystic ovary syndrome (PCOS). The image shows an enlarged ovary containing numerous small, well-defined, hypoechoic (fluid-filled) cystic structures distributed primarily in the peripheral stroma, often referred to as the 'string of pearls' sign. There are at least eight visible follicles of varying diameters. Two linear calipers mark the dimensions of the ovary, with measurements recorded at 2.54 cm and 1.74 cm. The ovarian stroma appears relatively hyperechoic and prominent. The image also exhibits characteristic ultrasound speckle artifact throughout the tissue. This visual is used in medical education to demonstrate the 'polycystic' component of the Rotterdam criteria for diagnosing PCOS, emphasizing the specific distribution and quantity of follicles and the increase in overall ovarian volume.

This diagnostic image is an endovaginal ultrasound of a human ovary, commonly associated with the diagnosis of polycystic ovary syndrome (PCOS). The ultrasound shows a transverse cross-section of the ovary characterized by an increased volume and specific follicular distribution. Numerous small, hypoechoic to anechoic cystic structures (follicles), typically measuring 2–8 mm in diameter, are visible. These follicles are arranged in a classic subcapsular distribution, lining up along the periphery of the organ to create the characteristic 'string-of-pearls' sign. The central portion of the ovary consists of a prominent, hyper-echodense ovarian stroma, which appears brighter relative to the dark peripheral cysts. This imaging pattern is a hallmark sonographic criterion for PCOS in the context of clinical signs like hirsutism or metabolic dysfunction. An inset image in the bottom right corner provides a visual analogy using a literal string of pearls to illustrate the diagnostic pattern.

This diagnostic image is an endovaginal ultrasound of a human ovary, commonly associated with the diagnosis of polycystic ovary syndrome (PCOS). The ultrasound shows a transverse cross-section of the ovary characterized by an increased volume and specific follicular distribution. Numerous small, hypoechoic to anechoic cystic structures (follicles), typically measuring 2–8 mm in diameter, are visible. These follicles are arranged in a classic subcapsular distribution, lining up along the periphery of the organ to create the characteristic 'string-of-pearls' sign. The central portion of the ovary consists of a prominent, hyper-echodense ovarian stroma, which appears brighter relative to the dark peripheral cysts. This imaging pattern is a hallmark sonographic criterion for PCOS in the context of clinical signs like hirsutism or metabolic dysfunction. An inset image in the bottom right corner provides a visual analogy using a literal string of pearls to illustrate the diagnostic pattern.

Reading File
Reading File
Reading File
Finding Sources
Now I have enough rich content to compile a thorough answer.

Treatment of Polycystic Ovary Syndrome (PCOS)

PCOS is the most common endocrine disorder in women of reproductive age, affecting 5-10% of women worldwide. It is characterised by hyperandrogenism, chronic anovulation, and polycystic ovarian morphology, frequently associated with insulin resistance and obesity. Treatment is goal-directed - management differs depending on whether the primary concern is menstrual regulation, hyperandrogenism, metabolic risk, or fertility.
PCOS ultrasound showing classic 'string of pearls' appearance

1. Lifestyle Modification (All Women with PCOS)

Lifestyle management is recommended for all women with PCOS regardless of phenotype. Weight loss of even 5-10% in overweight/obese women can restore ovulation, reduce androgen levels, and improve insulin sensitivity. This includes:
  • Caloric restriction and dietary changes (low glycaemic index diet preferred)
  • Regular aerobic and resistance exercise
  • Behavioural counselling for weight management
A 2025 systematic review (PMID: 39861440) confirms lifestyle interventions improve hormonal profiles, metabolic markers, and menstrual regularity in PCOS.

2. Menstrual Regulation and Endometrial Protection

Combined oral contraceptive pills (COCPs) are the first-line treatment in women not seeking pregnancy. They work by:
  • Suppressing LH and reducing ovarian androgen production
  • Increasing sex hormone-binding globulin (SHBG), which lowers free androgens
  • Protecting the endometrium from unopposed oestrogen (which risks hyperplasia/carcinoma)
The lowest effective oestrogen dose should be used, in cyclic or continuous manner.
Alternative endometrial protection (if COCPs are contraindicated):
  • Medroxyprogesterone acetate 10 mg/day, or progesterone 200 mg/day for 10-14 days every 3 months
  • Levonorgestrel intrauterine device (IUD)
(Harrison's Principles of Internal Medicine 22E)

3. Management of Hyperandrogenism (Hirsutism & Acne)

  • COCPs reduce androgens within 2-3 months, but hirsutism/acne improvement may take 6+ months
  • If COCP alone is inadequate after 6 months, add an antiandrogen:
    • Spironolactone (50-200 mg/day) - aldosterone antagonist with antiandrogenic properties; most widely used
    • Flutamide - non-steroidal antiandrogen; less commonly used due to hepatotoxicity risk
    • Finasteride - 5-alpha reductase inhibitor; used for hirsutism
  • Cosmetic measures (laser hair removal, electrolysis, waxing) are adjuncts, not substitutes
  • All antiandrogens require effective contraception due to teratogenicity risk

4. Metabolic and Cardiometabolic Risk Reduction

All women with PCOS should be screened at diagnosis and regularly for:
  • Obesity and BMI
  • Hypertension
  • Glycaemic control (fasting glucose, HbA1c, or OGTT)
  • Fasting lipid profile (in overweight/obese women)
  • Depression and anxiety
Metformin is recommended for overweight/obese women to reduce cardiometabolic risk factors (insulin resistance, dyslipidaemia, dysglycaemia). It is not first-line for hirsutism, endometrial protection, or infertility alone.
A 2024 meta-analysis (PMID: 39178623) shows GLP-1 receptor agonists (e.g. semaglutide, liraglutide) are effective in PCOS women with obesity, promoting significant weight loss and improving hormonal parameters - an emerging treatment option.

5. Fertility / Ovulation Induction (Women Seeking Pregnancy)

AgentRole
Letrozole (aromatase inhibitor)First-line for ovulation induction
Clomiphene citrate (SERM)Second-line; used with or without metformin
MetforminAdjunct to diet/exercise; may improve clomiphene response
Injectable gonadotropins (FSH/LH)Used by specialists when oral agents fail; risk of ovarian hyperstimulation syndrome (OHSS) is higher in PCOS
Ovarian drilling (laparoscopic)Surgical option for clomiphene-resistant PCOS; reduces androgen output
IVFFor women who fail all of the above
  • Letrozole is now preferred over clomiphene as it carries a lower multiple pregnancy risk and higher live birth rate
  • Metformin combined with clomiphene may improve ovulation rates compared to clomiphene alone
  • PCOS increases the risk of OHSS, so gonadotropins must be used cautiously
(Berek & Novak's Gynecology; Harrison's 22E)

6. Pregnancy-Related Considerations

Women with PCOS are at higher risk of:
  • Early miscarriage
  • Gestational diabetes
  • Gestational hypertension and pre-eclampsia
  • Preterm birth
Prepregnancy counselling and lifestyle optimisation are recommended before attempting conception. Metformin is not recommended for prevention of gestational diabetes in PCOS.

7. Surgical Treatment

Laparoscopic ovarian drilling (LOD): Electrocautery or laser punctures of ovarian follicles. Reserved for clomiphene-resistant PCOS in women who require laparoscopy for other reasons or cannot tolerate/afford gonadotropins. Reduces androgen levels and can restore ovulation for 6-12 months.

Summary Table

GoalFirst-lineSecond-line / Add-on
Menstrual regulationCOCPCyclic progestins, LNG-IUD
HyperandrogenismCOCPSpironolactone, flutamide
Metabolic riskLifestyle + metforminGLP-1 agonists (emerging)
Ovulation inductionLetrozoleClomiphene ± metformin, gonadotropins
Surgical-Ovarian drilling (selected cases)

Key recent evidence:
Sources: Harrison's Principles of Internal Medicine 22E (2025); Berek & Novak's Gynecology; Textbook of Family Medicine 9e
This is a shared conversation. Sign in to Orris to start your own chat.